JAN 0 3 2006 Thereby certify that Service with sufficient

hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

December 29, 2005

Signature:

(Sharon M. Siglich)

Docket No.: 28335/40012

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Kelly R. Clark et al.

Application No.: 10/789,303

Filed: February 26, 2004

For: RECOMBINANT ADENO-ASSOCIATED

VIRUS PRODUCTION

Confirmation No.: 8089

Art Unit: 1653

Examiner: M. Burkhart

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

Application No.: 10/789,303 Docket No.: 28335/40012

This Information Disclosure Statement is being submitted after receipt of the first office action on the merits but before the mailing of a final Office Action or Notice of Allowance. Therefore, our check in the amount of \$180.00 covering the fee set forth in 37 CFR §1.17(p) is enclosed. The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 13-2855, under Order No. 28335/40012. A duplicate copy of this paper is enclosed.

Dated: December 29, 2005

Respectfully submitted,

Sharon M. Sintich Registration No.: 48,484

MARSHALL, GERSTEIN & BORUN LLP

233 S. Wacker Drive, Suite 6300

Sears Tower

Chicago, Illinois 60606-6357

(312) 474-6300

Attorney for Applicant

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/B/PTO Application Number 10/789,303 INFORMATION DISCLOSURE February 26, 2004 Filing Date STATEMENT BY APPLICANT First Named Inventor Kelly Reed Clark et al. Art Unit 1653 (Use as many sheets as necessary) Examiner Name M. Burkhart Sheet 1 2 Attorney Docket Number 28335/40012

U.S. PATENT DOCUMENTS							
Evaminas	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Wher		
Examiner Initials*		Number-Kind Code ² (if known)			Relevant Passages or Relevant Figures Appear		
		5,622,856	04-22-1997	Natsoulis			
		5,658,776	08-19-1997	Flotte et al.			
		5,658,785	08-19-1997	Johnson			
		5,837,484	11-17-1998	Trempe et al.			
		6,258,595	07-10-2001	Gao et al.			
		6,365,403	04-02-2002	Natsoulis et al.			
	•	6,475,769	11-05-2002	Wilson et al.			
		6,541,258	04-01-2003	Allen et al.			

FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
	-,	WO99/41399	08-19-1999	Wadsworth					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \(^1\)Applicant's unique citation designation number (optional). \(^2\)See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. \(^3\)Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \(^4\)For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \(^5\)Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \(^6\)Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS			
Examiner Initials					
		Aitken et al., Hum Gene Therapy, "A Phase I Study of Aerosolized Administration of tgAAVCF to Cystic Fibrosis Subjects with Mild Lung Disease", 12:1907-1916 (2001)			
		Carter et al., AAV Vectors for Gene Therapy, in Gene and Cell Therapy: Therapeutic Mechanisms and Strategies, Second Edition (Ed. N. Templeton-Smith), pp. 71-101, Marcel Dekker, New York, 2004			
		Clark et al., Hum Gene Therapy, "Cell Lines for the Production of Recombinant Adeno- Associated Virus", 6:1329-1341 (1995)			
		Clark et al., Gene Therapy, "A stable cell line carrying adenovirus-inducible rep and cap genes allows for infectivity titration of adeno-associated virus vectors", 3:1124-1132 (1996)			
		Clark et al., Hum Gene Therapy, "Recombinant Adeno-Associated Viral Vectors Mediate Long-Term Transgene Expression in Muscle", 8(6):659-669 (1997)			
		Clark et al., Hum Gene Therapy, "Highly Purified Recombinant Adeno-Associated Virus Vectors Are Biologically Active and Free of Detectable Helper and Wild-Type Viruses", 10(6):1031-1039 (1999)			
		Fan and Dong, Human Gene Therapy, "Replication of rep-cap Genes Is Essential for the High- Efficiency Production of Recombinant AAV", 8:87-98 (1997)			
		Gao et al., Molecular Therapy, "Rep/Cap Gene Amplification and High-Yield Production of AAV in an A549 Cell Line Expressing Rep/Cap", 5(5):644-649 (2002).			
		Graham and Prevec, Mol. Biotechnol., "Methods for Construction of Adenovirus Vectors",			

Examiner	Date	
Signature	Considered	

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE spond to a collection of information unless it contains a valid OMB control number.

	Character of the restriction of the persons are required to respond to a concession and restricts it contains a valid only containing								
Sub	stitute for form 1449A/B/PT	0		Complete if Known					
				Application Number	10/789,303				
11	IFORMATION	1 DI	SCLOSURE	Filing Date	February 26, 2004				
S	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Kelly Reed Clark et al.				
				Art Unit	1653				
	(Use as many sh	eets as	necessary)	Examiner Name	M. Burkhart				
Sheet	2	of	2	Attorney Docket Number	28335/40012				

г	12,007,000 (4005)	
	3:207-220 (1995)	_
	Handbook of Parvoviruses, Vol. I (P. Tjissen, ed.) CRC Press, Boca Raton, pp 255-282 (1989)	_
	Leonard and Berns, <i>Virology</i> , "Cloning, Expression, and Partial Purification of Rep78: An Adeno-Associated Virus Replication Protein", 200 :566-573 (1994)	
	Li et al., J. Virol., "Role for Highly Regulated rep Gene Expression in Adeno-Associated Virus Vector Production", 71:5236-5243 (1997)	
	Liu et al., Molecular Therapy, "Selective Rep-Cap Gene Amplification as a Mechanism For High-Titer Recombinant AAV Production From Stable Cell Lines", 2(4):394-403 (2000).	
	Matsushita et al., Gene Therapy, "Adeno-associated virus vectors can be efficiently produced without helper virus", 5:938-945 (1998)	
	Muzyczka, Current Topics in Microbiology and Immunology, "Use of Adeno-Associated Virus as a General Transduction Vector for Mammalian Cells", 158 :97-129 (1992)	
	Nony et al., J. Virol., "Novel cis-Acting Replication Element in the Adeno-Associated Virus Type 2 Genome is Involved in Amplification of Integrated rep-cap Sequences", 75(20):9991-9994 (2001).	
	Pereira et al., J. Virol., "The Adeno-Associated Virus (AAV) Rep Protein Acts as Both a Repressor and an Activator to Regulate AAV Transcription during a Productive Infection", 71(2):1079-1088 (1997).	
	Ruffing et al., J. Gen. Virol., "Mutations in the carboxy terminus of adeno-associated virus 2 capsid proteins affect viral infectivity: lack of an RGD integrin-binding motif", 75:3385-3392 (1994)	
	Srivastava et al., J. Virol., "Nucleotide Sequence and Organization of the Adeno-Associated Virus 2 Genome", 45:555-564 (1983)	
	Vincent et al., J. Virol., "Analysis of Recombinant Adeno-Associated Virus Packaging and Requirements for rep and cap Gene Products", 71:1897-1905 (1997)	
	Xiao et al., J. Virol., "Production of High-Titer Recombinant Adeno-Associated Virus Vectors in the Absence of Helper Adenovirus", 72 :2224-2232 (1998)	
		_
		_
		_
		_
		_

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner			Date	
Signature			Considered	
	· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·		

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.